

Patricia Marinello,

PharmD, Executive Director, Program Development Lead MSI-H/CRC/ Hematology

Patricia Marinello, is an Executive Director from the division of Oncology Late Development at MSD, where she leads the Keytruda (pembrolizumab; anti PD-1) development teams for MSI-H agnostic, Colorectal Cancer and Hematology. Prior to her current role, Dr Marinello was Director of late development Oncology Clinical Research at Bristol-Myers Squibb (BMS) where she was involved in the development of Elotuzumab (anti-CS1) monoclonal antibody in multiple myeloma and was the Medical Lead for the development of Necitumumab (anti-EGFR monoclonal antibody) in lung cancer. Before BMS , Dr Marinello was the Director of clinical development at the Center of Molecular Immunology (CIM), a biotechnology company, which develops different modalities of immunotherapy for the treatment of cancer and infectious disease. Dr Marinello obtained her Doctor in Pharmacy degree from the University of Havana , where she earned an additional Master degree in Experimental Immuno-Pharmacology.